We found that TK1 presented with frequent structural variants, and copy number amplification indicated enhanced TK1 expression in diverse tumors, including breast invasive carcinoma, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, uterine corpus endometrial carcinoma, and SKCM (Figure 1B). This evidence concerns the gene TK1 and ovarian serous cystadenocarcinoma.